Joel E. Gallant, M.D., M.P.H.
Credit: MedPage Today via Joel Gallant
Dr. Gallant, one of the leading HIV specialists in the United States, is a professor of medicine and epidemiology in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine in Baltimore, Md., and professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is also the associate director of the Johns Hopkins AIDS Service and director of the Garey Lambert Research Center, which conducts a wide range of clinical trials on HIV treatment.
In addition to caring for HIV-infected patients and directing a large HIV clinic, Dr. Gallant is actively involved in research on the natural history of HIV-associated opportunistic infections, as well as the treatment of HIV and its complications. He has authored or co-authored many research articles that have been published in major, peer-reviewed journals, and is a frequent presenter at the world's largest HIV/AIDS medical conferences. Dr. Gallant has also written a large number of HIV conference reports, as well as topical overviews of HIV medicine and disease management -- many of which appear in The Hopkins HIV Report, of which Dr. Gallant is the associate editor. He is also the editor of the Johns Hopkins HIV Guide, a web-based educational tool, and is on the editorial board of the Johns Hopkins AIDS Service Web site. Dr. Gallant and his colleague, the noted HIV researcher John G. Bartlett, M.D., are co-authors of Medical Management of HIV Infection, a respected, annually updated clinical guide.
Dr. Gallant earned his medical degree at the University of California-San Francisco School of Medicine before completing his residency at Yale-New Haven Hospital in Connecticut and his fellowship at the Johns Hopkins University School of Medicine. Dr. Gallant also holds a master's degree in public health, which he earned from the Johns Hopkins University School of Hygiene and Public Health. Dr. Gallant is a fellow in the Infectious Diseases Society of America and the American College of Physicians and is a member of the HIV Medical Association and the American Academy of HIV Medicine.
Dr. Gallant has received research support from Gilead Sciences, GlaxoSmithKline, Merck & Co., Pfizer, Inc., Roche Laboratories and Tibotec. He serves on advisory boards for Bristol-Myers Squibb, Gilead Sciences, Merck, Panacos Pharmaceuticals, Pfizer, Inc., Schering-Plough Corporation and Tibotec. He has been a consultant for Abbott Laboratories, GlaxoSmithKline and Vertex Pharmaceuticals. He serves on the data and safety monitoring board for Abbott, Gilead Sciences and Koronis Pharmaceuticals. In addition, he has received honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences and Tibotec.
Latest by Joel E. Gallant, M.D., M.P.H.
Joel Gallant, M.D., covers the basics of starting or switching an HIV drug regimen in this comprehensive review of treatment options.
"There's a growing recognition ... that starting therapy with integrase inhibitors may be the best way to go for most people, and there are now two integrase inhibitor-based STRs to choose from: Stribild and Triumeq," writes leading HIV physician Joe...
Today, there are more treatment options than ever before for a person newly diagnosed with HIV. How does a doctor choose?
Dr. Gallant: Could you explain to me what is the difference between IGG and IGM antibodies. I Know that when you get infected your body produces both kinds, but only the IGg remains present and the Igm desapears. Why is that? When do you test positiv...